Hims & Hers Health (NYSE:HIMS) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Hims & Hers Health (NYSE:HIMS) issued its quarterly earnings data on Monday. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.03), FiscalAI reports. The business had revenue of $890.37 million for the quarter, compared to analyst estimates of $893.13 million. Hims & Hers Health had a negative net margin of 6.65% and a negative return on equity of 9.62%. Hims & Hers Health’s revenue for the quarter was up 48.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.06 EPS.

Here are the key takeaways from Hims & Hers Health’s conference call:

• Revenue grew 49% year over year to $890 million, accelerating for a second consecutive quarter; domestic revenue growth also improved to 21%. Adjusted EBITDA was $82 million, and the company generated $26 million of free cash flow.
• Subscribers fell by 100,000 sequentially to 2.8 million, which management attributed largely to deliberately lower U.S. weight-loss marketing and international brand migrations. The company expects subscriber headwinds to continue in Q4, with growth recovery anticipated after marketing ramps up in Q1.
• Hims & Hers lowered its 2026 Adjusted EBITDA guidance to $257 million–$277 million and expects Q4 revenue growth to slow to 42%–45%. Gross margin declined about seven percentage points sequentially to 57%, primarily due to a greater mix of lower-margin branded weight-loss products internationally.
• The company is expanding weight-loss options through Lilly and Novo partnerships, and raised its 2026 international revenue expectation to at least $650 million. Management says the AI-native experience reached 70% of weight-loss subscribers and users send four times as many messages, though these investments and broader international marketing may weigh on near-term results.
• Hims & Hers plans to launch Peptides+ later this month and recently expanded injectable and oral testosterone offerings, using its own pharmacy and lab infrastructure. Peptide revenue is not expected to be material in Q4, and some planned products depend on regulatory clarity.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock traded up $1.73 during mid-day trading on Wednesday, hitting $20.86. 23,622,758 shares of the stock were exchanged, compared to its average volume of 14,708,043. The company has a 50-day simple moving average of $27.95 and a 200 day simple moving average of $26.80. The company has a debt-to-equity ratio of 3.85, a quick ratio of 0.87 and a current ratio of 0.92. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $40.99. The company has a market capitalization of $4.87 billion, a P/E ratio of -25.13 and a beta of 2.53.

Latest Hims & Hers Health News

These are some of the HIMS news items that stood out recently:

• Negative Sentiment: Third-quarter results disappointed: Hims & Hers reported a surprise loss, missed earnings and revenue estimates, and gross margin fell to 57.2% from 73.8% a year earlier. Subscribers also declined by 100,000 sequentially to 2.8 million. Article: Hims & Hers Q3 Earnings Miss Estimates, Gross Margin Down
• Negative Sentiment: Management lowered its 2026 adjusted EBITDA outlook to $257 million–$277 million, and fourth-quarter revenue guidance of $875 million–$895 million came in well below analysts’ expectations. The cut adds to concerns about the company’s earnings trajectory. Article: Hims & Hers Cuts 2026 Earnings Outlook
• Negative Sentiment: Five states have joined an FTC lawsuit alleging unlawful privacy practices, creating additional legal and reputational risk. Analysts also lowered price targets, including Morgan Stanley, which maintained an equal-weight rating while cutting its target from $28 to $25. Article: Five US States Join FTC Suit Against Hims & Hers

Insider Activity

In other news, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $28.39, for a total transaction of $398,226.53. Following the completion of the sale, the chief operating officer directly owned 456,660 shares of the company’s stock, valued at approximately $12,964,577.40. The trade was a 2.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Deborah Autor sold 16,773 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $27.85, for a total transaction of $467,128.05. Following the completion of the sale, the insider directly owned 48,961 shares of the company’s stock, valued at $1,363,563.85. This represents a 25.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 133,905 shares of company stock valued at $3,826,977 over the last 90 days. Company insiders own 11.76% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on HIMS. Weiss Ratings reiterated a “sell (d)” rating on shares of Hims & Hers Health in a research report on Wednesday, November 4th. Truist Financial raised their price objective on Hims & Hers Health from $27.00 to $32.00 and gave the stock a “hold” rating in a research note on Monday, August 24th. Deutsche Bank lifted their target price on Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. initiated coverage on Hims & Hers Health in a research note on Friday, September 11th. They issued a “neutral” rating and a $32.00 price target on the stock. Finally, TD Cowen boosted their price target on Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $31.53.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.